BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data abstracts from its Phase 2 trials evaluating NE7107 in degenerative dementias and Parkinson’s Disease will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, to be held virtually and in Boston, MA, April 22-27, 2023.
Details for the presentations are as follows:
New Poster - Multi-Modal Correlation Analyses from a Phase 2, Open-Label Study of NE3107 in Patients with Cognitive Decline Due to Degenerative Dementias
- Presentation date/time: 4/25/23 @8:00-9:00am ET
- Presenter: Joseph Palumbo
- Abstract: https://www.aan.com/MSA/Public/Events/AbstractDetails/54170
Encore Poster - Clinical Outcomes from a Phase 2, Open-Label Study of NE3107 in Patients with Cognitive Decline Due to Degenerative Dementias
- Presentation date/time: 4/25/23 @11:45am-12:45pm ET
- Presenter: Kaya Jordan
- Abstract: https://www.aan.com/MSA/Public/Events/AbstractDetails/54177
Encore Poster - Safety, Tolerability, and Efficacy of NE3107 from a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients with Parkinson's Disease
- Presentation date/time: 4/23/23 @8:00-9:00am ET
- Presenter: Nilab Osman
- Abstract: https://www.aan.com/MSA/Public/Events/AbstractDetails/54740
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.